Valuation: Agenus Inc.

Market Cap 375M 333M 311M 284M 534M 36.11B 542M 3.77B 1.46B 18.39B 1.41B 1.38B 59.06B P/E 2026 *
33.8x
P/E 2027 * -17.6x
Enterprise Value 375M 333M 311M 284M 534M 36.11B 542M 3.77B 1.46B 18.39B 1.41B 1.38B 59.06B EV / Sales 2026 *
3x
EV / Sales 2027 * 3.23x
Free-Float
93.76%
Yield 2026 *
-
Yield 2027 * -
1 day-16.11%
1 week-2.00%
Current month-16.11%
1 month+4.26%
3 months+144.28%
6 months+145.00%
Current year+165.29%
1 week 8.28
Extreme 8.28
10.31
1 month 6.66
Extreme 6.66
10.31
Current year 2.71
Extreme 2.71
10.31
1 year 2.71
Extreme 2.71
10.31
3 years 1.38
Extreme 1.38
23.2
5 years 1.38
Extreme 1.38
117.2
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 30/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/10/2021
Director TitleAgeSince
Chairman 73 03/11/2010
Director/Board Member 68 07/03/2007
Director/Board Member 68 06/12/2006
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Chief Executive Officer

1,971,500 4.4054%
05/08/26 Free

Director

50,000 0.1117%
05/08/26 Free

Director

50,000 0.1117%
Change 5-day change 1-year change 3-year change Capi.($)
-16.11%-2.00%+113.59%-63.14% 375M
+4.16%+3.04%+49.37%+94.17% 74.41B
-1.02%-1.44%+24.55%+78.37% 59.26B
+1.25%+0.14%+5.09%+35.55% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -2.07%+1.35%+59.00%+132.48% 39.28B
Weighted average by Cap. +0.03%-0.30%+58.18%+145.71%

Financials

2026 *2027 *
Net sales 125M 111M 104M 94.77M 178M 12.05B 181M 1.26B 487M 6.14B 470M 460M 19.72B 116M 103M 96.32M 87.78M 165M 11.17B 168M 1.17B 451M 5.69B 435M 426M 18.26B
Net income 39.4M 35M 32.73M 29.82M 56.15M 3.79B 56.92M 396M 153M 1.93B 148M 145M 6.21B -28.55M -25.36M -23.71M -21.61M -40.68M -2.75B -41.24M -287M -111M -1.4B -107M -105M -4.5B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
01/10/26 US$8.330 -16.11% 1,951,997
30/09/26 US$9.930 +0.40% 1,367,323
29/09/26 US$9.890 +4.88% 1,501,456
28/09/26 US$9.430 +10.42% 2,766,014
25/09/26 US$8.540 +0.47% 672,403
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.330USD
Average target price
26.33USD
Spread / Average Target
+216.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock